REFERENCES
1. Rallapalli, P. M., Kemball-Cook, G., Tuddenham, E. G., Gomez, K. & Perkins, S. J. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J. Thromb. Haemost. 11 , 1329–1340 (2013).
2. Hart, D. P. et al. International consensus recommendations on the management of people with haemophilia B. Ther. Adv. Hematol.13 , (2022).
3. Peyvandi, F., Garagiola, I. & Young, G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet388 , 187–197 (2016).
4. Graf, L. Extended Half-Life Factor VIII and Factor IX Preparations.Transfus. Med. Hemotherapy 45 , 86–91 (2018).
5. Powell, J. S. et al. Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. N. Engl. J. Med. 369 , 2313–2323 (2013).
6. Dolan, G. et al. Haemophilia B: Where are we now and what does the future hold? Blood Rev. 32 , 52–60 (2018).
7. Björkman, S. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.Haemophilia 19 , 808–813 (2013).
8. Kisker, C. T. et al. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 9 , 279–284 (2003).
9. Björkman, S. & Åhlén, V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur. J. Clin. Pharmacol.68 , 969–977 (2012).
10. Iorio, A. Using pharmacokinetics to individualize hemophilia therapy. Hematology 2017 , 595–604 (2017).
11. Björkman, S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 9 , 101–110 (2003).
12. Björkman, S., Shapiro, A. D. & Berntorp, E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: Implications for dosing in prophylaxis. Haemophilia 7 , 133–139 (2001).
13. Megías-Vericat, J. E. et al. Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate®) and BAY 81-8973 (Kovaltry®) in patients with severe or moderate haemophilia A in prophylaxis.Haemophilia 25 , e215–e218 (2019).
14. Solms, A., Lalezari, S., Shah, A. & Kenet, G. Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection. Haemophilia 26 , e145–e147 (2020).
15. Iorio, A. et al. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Res. Pract. Thromb. Haemost.2 , 535–548 (2018).
16. Diao, L. et al. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin. Pharmacokinet. 53 , 467–477 (2014).
17. Goedhart, T. M. H. J. et al. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). TH Open 06 , e60–e69 (2022).
18. Preijers, T. et al. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. J. Thromb. Haemost.16 , 2196–2207 (2018).
19. Björkman, S., Carlsson, M. & Berntorp, E. Pharmacokinetics of factor IX in patients with haemophilia B - Methodological aspects and physiological interpretation. Eur. J. Clin. Pharmacol.46 , 325–332 (1994).
20. Carlsson, M., Björkman, S. & Berntorp, E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.Haemophilia 4 , 83–88 (1998).
21. EMA. Alprolix® (Eftrenonacog alfa) Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf (2023).
22. EMA. Benefix® (Nonacog alfa) Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/benefix-epar-product-information_en.pdf (2023).
23. EMA. Idelvion® (Albutrepenonacog alfa) Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (2023).
24. Abrantes, J. A., Jönsson, S., Karlsson, M. O. & Nielsen, E. I. Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data. Br. J. Clin. Pharmacol.85 , 1326–1336 (2019).
25. Beal, S. L., Sheiner, L. B. & Bauer, R. J. NONMEM 7.4 Users Guides. at https://nonmem.iconplc.com/nonmem741 (2017).
26. Iorio, A. et al. Tailoring treatment of haemophilia B: Accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb. Haemost. 117 , 1023–1030 (2017).
27. Mandema, J. W., Verotta, D. & Sheiner, L. B. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects.J. Pharmacokinet. Biopharm. 20 , 511–528 (1992).
28. Wahlby, U., Jonsson, E. N. & Karlsson, M. O. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci4 , 68–79 (2002).
29. Anderson, B. J. & Holford, N. H. G. Tips and traps analyzing pediatric PK data. Paediatr. Anaesth. 21 , 222–237 (2011).
30. Anderson, B. J. & Holford, N. H. G. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48 , 303–332 (2008).
31. Mould, D. R. & Upton, R. N. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods. CPT Pharmacometrics Syst. Pharmacol. 2 , e38 (2013).
32. Hooker, A. C., Staatz, C. E. & Karlsson, M. O. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24 , 2187–2197 (2007).
33. Bukkems, L. H. et al. A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. Thromb. Haemost.120 , 747–757 (2020).
34. Hardiansyah, D. & Ng, C. M. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling. MAbs 10 , 1144–1156 (2018).
35. Turecek, P. L., Johnsen, J. M., Pipe, S. W. & O’Donnell, J. S. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. Haemophilia 26 , 575–583 (2020).
36. Björkman, S. et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 119 , 612–618 (2012).
37. Shapiro, A. D. et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 119 , 666–672 (2012).
38. Roth, D. A. et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98 , 3600–3606 (2001).
39. Uprichard, J., Adamidou, D., Goddard, N. J., Mann, H. A. & Yee, T. T. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010. Haemophilia18 , 46–49 (2012).
40. Stafford, D. W. Extravascular FIX and coagulation. Thromb. J.14 , (2016).
41. Gui, T. et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J. Thromb. Haemost. 7 , 1843–1851 (2009).
42. Cooley, B. et al. Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood 128 , 286–292 (2016).